3 Things You Should Know About Geographic Atrophy

Slides:

Advertisements

Similar presentations

Medical Retina and Macular Diseases

Advertisements

Anti VEGF Options in the management of CNV 1)Observation  occult CNV also requires close follow – up.every 3 month 2) Laser coagulation 3) Surgery.

IMAGING in AMD From Fluorescein Angiography To the Spectral Domain OCT

Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):

CERA Age-related macular degeneration- (AMD) information forum

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Outer Retinal Tubulation as a Predictor of the Growth Rate of Geographic Atrophy in Age Related Macular Degeneration Amirhossein Hariri 1, Muneeswar G.

Volume 1, Issue 1, Pages (January 2017)

Invest. Ophthalmol. Vis. Sci ;54(14):ORSF68-ORSF80. doi: /iovs

Moderate-to-Severe Asthma Management

Systemic Lupus Erythematosus

Clinical Trials in IBD.

Treatment Algorithms in Melanoma: Past, Present, and Future

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Applying Biosimilars in Hematologic Cancers

Advances in Managing Inhibitors in Patients With Hemophilia A

Dry AMD and GA: The Present and Future

Progression After Cancer Immunotherapy in Advanced NSCLC

New Therapies in Alzheimer's Disease

Immune Reconstitution in MS:

Geographic Atrophy in a Clinical Trial Environment

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Advances in Dry Eye.

A new way to see abnormal blood vessels in AMD

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Chronic Idiopathic Urticaria

The Nurse View.

Treatment Decisions in Chemorefractory Follicular Lymphoma

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Updates in Detection and Management of BCRPC

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Nontuberculous Mycobacterial Lung Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Multiple Myeloma

Management of CMV in HSCT Recipients

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Ask the Experts.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

AMD update Macular research.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Developments in the Wet AMD Treatment Landscape

Volume 4, Issue 5, Pages (May 2015)

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

The Role of Maintenance Therapy in Multiple Myeloma

Evaluating BTK Inhibitors in CLL

Pregnancy in MS.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

(case 6) (A) Fundus photography showing subtle discrete areas of RPE atrophy (green areas). (case 6) (A) Fundus photography showing subtle discrete areas.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in Progressive MS

Presentation transcript:

3 Things You Should Know About Geographic Atrophy

This program will include a discussion of off-label and investigational agents not approved by the FDA for use in the United States.

Geographic Atrophy: A Clinician's Challenge

AREDS Classification Early and Intermediate AMD

Advanced AMD: "Wet" vs "Dry"

Affects of GA on Vision

Rate of GA Progression

Treatability: CNV vs GA

Therapeutic Approaches Visual Cycle Modulation

Therapeutic Approaches Anti-Amyloid ß Therapy

Therapeutic Approaches Neuroprotection

Therapeutic Approaches Suppress Inflammation/Complement Inhibition

Therapeutic Approaches Components of the Complement System

Factor D Inhibition: Lampalizumab

C3 Inhibition: APL-2

Therapeutic Approaches Stem Cell Therapy

Early GA Detection is Key

Fundus Photography

Autofluorescence Imaging

SD OCT

Fluorescein Angiography

Tracking the Progression of GA

3 Key Takeaways